FDA Warning Wire: New Woes For Wockhardt
Law360, New York (January 19, 2016, 6:37 PM ET) -- Beleaguered Indian drugmaker Wockhardt leads this week’s look at U.S. Food and Drug Administration enforcement actions after inspectors criticized numerous issues at a new manufacturing plant. FDA officials also complained about a medical device maker’s promotional claims and a compounding pharmacy's decision to let dogs hang out near its laboratory.
Inspectors Fault New Wockhardt Plant
The criticism of Wockhardt Ltd. came in a so-called 483 inspection report. According to the company, FDA inspectors identified nine areas of violations. The nature of the violations was not disclosed,...
Inspectors Fault New Wockhardt Plant
The criticism of Wockhardt Ltd. came in a so-called 483 inspection report. According to the company, FDA inspectors identified nine areas of violations. The nature of the violations was not disclosed,...
To view the full article, register now.
No comments:
Post a Comment